Collegium Pharmaceutical (NASDAQ:COLL) Shares Up 3.8%

Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Get Free Report)'s share price shot up 3.8% during mid-day trading on Tuesday . The stock traded as high as $38.12 and last traded at $38.12. 38,601 shares changed hands during mid-day trading, a decline of 91% from the average session volume of 420,141 shares. The stock had previously closed at $36.71.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the stock. StockNews.com raised shares of Collegium Pharmaceutical from a "buy" rating to a "strong-buy" rating in a report on Tuesday, April 23rd. Jefferies Financial Group reaffirmed a "hold" rating and set a $37.00 price objective (up from $30.00) on shares of Collegium Pharmaceutical in a report on Thursday, January 4th. Needham & Company LLC reissued a "buy" rating and issued a $40.00 target price on shares of Collegium Pharmaceutical in a report on Thursday, April 11th. Piper Sandler reaffirmed an "overweight" rating and issued a $39.00 price target (up previously from $37.00) on shares of Collegium Pharmaceutical in a research note on Friday, February 23rd. Finally, Truist Financial increased their price objective on Collegium Pharmaceutical from $37.00 to $40.00 and gave the stock a "buy" rating in a research note on Monday, February 26th. Two analysts have rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, Collegium Pharmaceutical has a consensus rating of "Moderate Buy" and an average target price of $39.00.

Collegium Pharmaceutical Trading Up 0.6 %

The company has a 50-day simple moving average of $37.22 and a 200-day simple moving average of $31.47. The company has a debt-to-equity ratio of 2.48, a quick ratio of 1.10 and a current ratio of 1.17. The stock has a market cap of $1.21 billion, a P/E ratio of 31.30 and a beta of 1.03.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last issued its quarterly earnings data on Thursday, February 22nd. The specialty pharmaceutical company reported $1.45 EPS for the quarter, topping analysts' consensus estimates of $1.20 by $0.25. Collegium Pharmaceutical had a net margin of 8.50% and a return on equity of 107.39%. The firm had revenue of $149.75 million for the quarter, compared to analyst estimates of $147.66 million. On average, sell-side analysts forecast that Collegium Pharmaceutical, Inc. will post 5.63 EPS for the current fiscal year.

Institutional Trading of Collegium Pharmaceutical

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Pacer Advisors Inc. grew its position in shares of Collegium Pharmaceutical by 68.4% during the 4th quarter. Pacer Advisors Inc. now owns 2,174,718 shares of the specialty pharmaceutical company's stock worth $66,938,000 after buying an additional 883,380 shares during the period. Penn Capital Management Company LLC bought a new position in shares of Collegium Pharmaceutical in the 4th quarter worth $9,755,000. Assenagon Asset Management S.A. grew its stake in shares of Collegium Pharmaceutical by 178.1% during the third quarter. Assenagon Asset Management S.A. now owns 425,630 shares of the specialty pharmaceutical company's stock worth $9,513,000 after purchasing an additional 272,565 shares during the period. New York State Common Retirement Fund lifted its stake in Collegium Pharmaceutical by 1,475.5% in the fourth quarter. New York State Common Retirement Fund now owns 201,112 shares of the specialty pharmaceutical company's stock valued at $6,190,000 after buying an additional 188,347 shares during the period. Finally, Qube Research & Technologies Ltd boosted its holdings in Collegium Pharmaceutical by 713.3% during the third quarter. Qube Research & Technologies Ltd now owns 127,010 shares of the specialty pharmaceutical company's stock worth $2,839,000 after buying an additional 111,394 shares during the last quarter.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.